The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kochatkov A.V.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Kriger A.G.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Gorin D.S.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Lebedeva A.N.

Otdelenie khirurgii sosudov Instituta khirurgii im. A.V. Vishnevskogo, Moskva

Pancreatic endocrine tumors

Authors:

Kochatkov A.V., Kriger A.G., Gorin D.S., Lebedeva A.N.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2010;(9): 71‑80

Read: 7298 times

Download PDF (RU)
Contact the author
Table of contents

PANCREATIC ENDOCRINE TUMORS
PANCREATIC ENDOCRINE TUMORS

To cite this article:

Kochatkov AV, Kriger AG, Gorin DS, Lebedeva AN. Pancreatic endocrine tumors. Pirogov Russian Journal of Surgery. 2010;(9):71‑80. (In Russ.)

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cystic-solid transformation of the pancreas and kidneys due to von Hippel-Lindau disease. Piro­gov Russian Journal of Surgery. 2025;(10):118-125
Abstract:

Keywords:

endocrine tumors
pancreas

Authors:

Kochatkov A.V.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Kriger A.G.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Gorin D.S.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Lebedeva A.N.

Otdelenie khirurgii sosudov Instituta khirurgii im. A.V. Vishnevskogo, Moskva

Close metadata

References:

  1. Gurevich L.E. Diagnostika neiroendokrinnykh opukholei zheludochno-kishechnogo trakta. Prakticheskaya onkologiya 2005; 6: 4: 193-200.
  2. Kuzin N.M., Egorov A.V. Neiroendokrinnye opukholi podzheludochnoi zhelezy. M: Meditsina 2001; 49-60.
  3. Akerstrom G., Hellman P. Surgery on neuroendocrine tumours. Best Practice & Research Clinical Endocrinology & Metabolism 2007; 21: 1: 87-10.
  4. Akerstrom G., Hessman O., Hellman P. et al. Pancreatic tumours as part of the MEN-1 syndrome. Best Pract Res Clin Gastroenterol 2005; 19: 819-830.
  5. Akerstrom G., Hessman O., Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbecks Arch Surg 2002; 386: 558-569.
  6. Alexakis N., Connor S., Ghaneh P. et al. Hereditary pancreatic endocrine tumours. Pancreatology 2004; 4: 417-435.
  7. Alexander H.R., Fraker D.L., Norton J.A. et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228: 228-238.
  8. Arnold R. Endocrine tumors of the gastrointestinal Tract. Part 11. Best Pract Res Clin Gastroenterol 2005; 19: 659-830.
  9. Arnold R., Rinke A., Muller H. Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide Lar in the control of tumor growth in patients with metastatic neuroendocrine tumors: a report from the PROMID Study Group. ASCO-GI Cancers Symposium 2009; 15.
  10. Arnold R., Rinke A., Schmidt C. et al. Chemotherapy. Best Pract Res Clin Gastroenterol 2005; 19: 649-656.
  11. Assalia A., Gagner M. Laparoscopic pancreatic surgery for islet cell tumors of the pancreas. World J Surg 2004; 28: 1239-1247.
  12. Barakat M.T., Meeran K., Bloom S.R. Neuroendocrine tumors. Endocr Relat Cancer 2004; 11: 1-18.
  13. Beger H.G., Matsuno S., Cameron J.L. et al. Diseases of the Pancreas 2008; 500-502.
  14. Binkovitz L.A., Johnson C.D., Stephens D.H. Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. Am J Roentgenol 1990; 155: 501-505.
  15. Bishop A.E., Polak J.M., Facer P. et al. Neuron specific enolase: a common marker for the endocrine cells and innervation of the gut and pancreas. Gastroenterology 1982; 83: 902-915.
  16. Broder L.E., Carter S.K. Pancreatic islet cell carcinoma. Clinical features of 52 patients. Ann Intern Med 1973; 79: 101-107.
  17. Broughan T.A., Leslie J.D., Soto J.M. et al. Pancreatic islet cell tumors. Surgery 1986; 99: 671-678.
  18. Buetow P.C., Miller D.L., Parrino T.V. et al. Islet cell tumors of the pancreas: clinical, radiologic, and pathologic correlation in diagnosis and localization. Radiographics 1997; 17: 453-472.
  19. Capella C., Heitz P.U., Hofler H. et al. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 55(Suppl 3) 1994; 11.
  20. Carty S.E., Jensen R.T., Norton J.A. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992; 112: 1024-1031.
  21. Chamberlain R.S., Canes D., Brown K.T. et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190: 432-445.
  22. Chen H., Hardacre J.M., Uzar A. et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187: 88-92.
  23. Cheslyn-Curtis S., Sitaram V., Williamson R.C. Management of non-functioning neuroendocrine tumors of the pancreas. Br J Surg 1993; 80: 625-627.
  24. Chu Q.D., Hill H.C., Douglass H.O. et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002; 9: 855-862.
  25. Collen M.J., Howard J.M., McArthur K.E. et al. Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. Ann Intern Med 1984; 100: 52-58.
  26. Corleto V.D., Annibale B., Gibril F. et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 2001; 15: 1555-1561.
  27. Corleto V.D., Panzuto F., Falconi M. et al. Digestive neuroendocrine tumors: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 2001; 33: 217-221.
  28. Couvelard A., O'Toole D., Turley H. et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumors: negative correlation of microvascular density and VEGF expression with tumor progression. Br J Cancer 2005; 92: 94-101.
  29. Curley S.A., Lott S.T., Luca J.W. et al. Surgical decision-making affected by clinical and genetic screening of a novel kindred with von Hippel-Lindau disease and pancreatic islet cell tumors. Ann Surg 1998; 227: 229-235.
  30. Danforth D.N., Gorden P., Brennan M.F. Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery 1984; 96: 1027-1037.
  31. DeLellis R.A., Lloyd R.V., Heitz P.U. WHO classification of tumours. Pathology and genetics, tumours of endocrine organs, chapter 4. 2004; IARC, Lyon.
  32. Dial P.F., Braasch J.W., Rossi R.L. et al. Management of nonfunctioning islet cell tumors of the pancreas. Surg Clin N Am 1985; 65: 291-299.
  33. Donow C., Pipeleers-Marichal M., Schroder S. et al. Surgical pathology of gastrinoma: site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer 1991; 68: 1329-1334.
  34. Dralle H., Krohn S.L., Karges W. et al. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg 2004; 28: 1248-1260.
  35. Eriksson B., Arnberg H., Lindgren P.G. et al. Neuroendocrine pancreatic tumors: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990; 228: 103-113.
  36. Evans D.B., Skibber J.M., Lee J.E. et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery 1993; 114: 1175-1181.
  37. Fidler J.L., Johnson C.D. Imaging of neuroendocrine tumors of the pancreas. Int J Gastrointest Cancer 2001; 30: 73-85.
  38. Finlayson E., Clark O.H. Surgical treatment of insulinomas. Surg Clin North Am 2004; 84: 775-785.
  39. Fishbeyn V.A., Norton J.A., Benya R.V. et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med 1993; 119: 199-206.
  40. Fraker D.L., Norton J.A., Alexander H.R. et al. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 1994; 220: 320-330.
  41. Gibril F., Jensen R.T. Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 2005; 7: 114-121.
  42. Gibril F., Jensen R.T. Diagnostic uses of radiolabelled somatostatin-receptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis 2004; 36: 106-120.
  43. Gibril F., Jensen R.T. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep 2004; 6: 454-463.
  44. Gibril F., Reynolds J.C., Doppman J.L. et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 1996; 125: 26-34.
  45. Grama D., Eriksson B., Martensson H. et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 1992; 16: 632-639.
  46. Graves T.D., Gandhi S., Smith S.J. et al. Misdiagnosis of seizures: insulinoma presenting as adult-onset seizure disorder. J Neurol Neurosurg Psychiatry 2004; 75: 1091-1092.
  47. Hellman P., Andersson M., Rastad J. et al. Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg 2000; 24: 1353-1360.
  48. House M.G., Cameron J.L., Lillemoe K.D. et al. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg 2006; 10: 138-145.
  49. Ichikawa T., Peterson M.S., Federle M.P. et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000; 216: 163-171.
  50. Jaroszewski D.E., Schlinkert R.T., Thompson G.B. et al. Laparoscopic localization and resection of insulinomas. Arch Surg 2004; 139: 270-274.
  51. Jensen R.T. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 477-488.
  52. Jensen R.T. Natural history of digestive endocrine tumors. Recent Advances in Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors. Paris, John Libbey Eurotext Publishing 1999; 192-219.
  53. Jensen R.T. Should the 1996 citation for Zollinger-Ellison syndrome read: "Acid-reducing surgery in, aggressive resections out?" Am J Gastroenterol 1996; 91: 1067-1070.
  54. Jensen R.T. Use of omeprazole and other proton pump inhibitors in the Zollinger-Ellison syndrome. Milestones in Drug Therapy. Basel, Birkhauser 1999; 205-221.
  55. Jensen R.T. Zollinger-Ellison syndrome. Surgical Endocrinology: Clinical Syndromes. Philadelphia, Lippincott Williams & Wilkins 2001; 291-344.
  56. Jensen R.T., Gardner J.D. The Pancreas:Biology, Pathobiology and Disease. New York, Raven Press 1993; 931-978.
  57. Jensen R.T. Gastrinomas: advances in diagnosis and management. Neuroendocrinology 2004; 80: 23-27.
  58. Kalra M.K., Maher M.M., Mueller P.R. et al. State-of-the-art imaging of pancreatic neoplasms. Br J Radiol 2003; 76: 857-865.
  59. Kimura W., Kuroda A., Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 1991; 36: 933-942.
  60. Klimstra D.S., Oberg K., Komminoth P. et al. Non-Functioning Tumors and Microadenomas. Lyon IARC Press 2004.
  61. Kloppel G., Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2005; 19: 507-517.
  62. Kloppel G., Heitz P.U. Pancreatic endocrine tumors. Pathol Res Pract 1988; 183: 155-168.
  63. Kouvaraki M.A., Ajani J.A., Hoff P. et al. Fluorouracil, doxorubicin, and streptozotocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22: 4762-4771.
  64. La Rosa S., Sessa F., Capella C. et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumors. Virchows Arch 1996; 429: 323-333.
  65. Legaspi A., Brennan M.F. Management of islet cell carcinoma. Surgery 1988; 104: 1018-1023.
  66. Lehnert H., Becker W., Dralle H. et al. Neuroendokrine Tumore des Gastrointestinaltrakts ed 2. Stuttgart, Georg Thieme Verlag 2003.
  67. Lloyd R.V., Wilson B.S. Specific endocrine tissue marker defined by a monoclonal antibody. Science 1983; 222: 628-630.
  68. MacFarlane M.P., Fraker D.L., Alexander H.R. et al. A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia-type 1. Surgery 1995; 118: 973-980.
  69. Madura J.A., Cummings O.W., Wiebke E.A. et al. Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort. Am Surg 1997; 63: 573-577.
  70. Marion-Audibert A.M., Barel C., Gouysse G. et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003; 125: 1094-1104.
  71. Maton P.N., Miller D.L., Doppman J.L. et al. Role of selective angiography in the management of Zollinger-Ellison syndrome. Gastroenterology 1987; 92: 913-918.
  72. Matthews B.D., Heniford B.T., Reardon P.R. et al. Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas. Am Surg 2000; 66: 1116-1122.
  73. McArthur K.E., Richardson C.T., Barnett C.C. et al. Laparotomy and proximal gastric vagotomy in Zollinger-Ellison syndrome: results of a 16-year prospective study. Am J Gastroenterol 1996; 91: 1104-1111.
  74. Metz D.C., Jensen R.T. Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Front Gastrointest Res Basel Karger 1995; 23: 240-257.
  75. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000; 62: 51-58.
  76. Mignon M., Jais P., Cadiot G. et al. Clinical features and advances in biological diagnostic criteria for Zollinger-Ellison syndrome. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Front Gastrointest Res. Basel, Karger 1995; 23: 223-239.
  77. Nave H., Mossinger E., Feist H. et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 2001; 129: 170-175.
  78. Norton J.A., Alexander H.A., Fraker D.L. et al. Possible primary lymph node gastrinomas: occurrence, natural history and predictive factors: A prospective study. Ann Surg 2003; 237: 650-659.
  79. Norton J.A., Alexander H.R., Fraker D.L. et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001; 234: 495-506.
  80. Norton J.A., Alexander H.R., Fraker D.L. et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg 2004; 239: 617-626.
  81. Norton J.A., Doherty G.M., Fraker D.L. Surgical treatment of localized gastrinoma within the liver: a prospective study. Surgery 1998; 124: 1145-1152.
  82. Norton J.A., Doppman J.L., Jensen R.T. Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg 1992; 215: 8-18.
  83. Norton J.A., Fraker D.L., Alexander H.R. et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244: 410-419.
  84. Norton J.A., Fraker D.L., Alexander H.R. et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635-644.
  85. Norton J.A., Jensen R.T. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004; 240: 757-773.
  86. Norton J.A., Kivlen M., Li M. et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003; 138: 859-866.
  87. Norton J.A., Sugarbaker P.H., Doppman J.L. et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg 1986; 203: 352-359.
  88. O'Riordain D.S., O'Brien T., van Heerden J.A. et al. Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg 1994; 18: 488-493.
  89. O'Toole D., Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19: 585-594.
  90. Oberg K., Skogseid B. The ultimate biochemical diagnosis of endocrine pancreatic tumors in MEN-1. J Intern Med 1998; 243: 471-476.
  91. Oberndorfer S. Karzinoide tumoren des dundarms. Frankf Z Pathol 1907; 1: 426-432.
  92. Owen N.J., Sohaib S.A., Peppercorn P.D. et al. MRI of pancreatic neuroendocrine tumors. Br J Radiol 2001; 74: 968-973.
  93. Panzuto F., Di Fonzo M., Iannicelli E. et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated enteropancreatic endocrine carcinoma. Ann Oncol 2006; 17: 461-466.
  94. Panzuto F., Nasoni S., Falconi M. et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2006; 12: 1083-1092.
  95. Pape U.F., Bohmig M., Berndt U. et al. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann NY Acad Sci 2004; 1014: 222-233.
  96. Pavel M. From symptom control to tumor control. In advanced in the treatment of neuroendocrine tumors. Achieving tumor control. Ecco/Esmo 2009; 9-10.
  97. Pederzoli P., Falconi M., Bonora A. et al. Cytoreductive surgery in advanced endocrine tumors of the pancreas. Ital J Gastroenterol Hepatol 1999; 31: 207-212.
  98. Perry R.R., Vinik A.I. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 1995; 80: 2273-2278.
  99. Phan G.Q., Yeo CJ, Hruban R.H. et al. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 1998; 2: 472-482.
  100. Philippe J., Powers A.C., Mojsov S. et al. Expression of peptide hormone genes in human islet cell tumors. Diabetes 1988; 37: 1647-1651.
  101. Plockinger U., Rindi G., Arnold R. et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424.
  102. Procacci C., Carbognin G., Accordini S. et al. Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization. Eur Radiol 2001; 11: 1175-1183.
  103. Que F.G., Nagorney D.M., Batts K.P. et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169: 36-42.
  104. Que F.G., Sarmiento J.M., Nagorney D.M. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Cancer Control 2002; 9: 67-79.
  105. Ramage J.K., Davies A.H., Ardill J. et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54 (Suppl 4): 1-16.
  106. Rappeport E.D., Hansen C.P., Kjaer A. et al. Multidetector computed tomography and neuroendocrine pancreaticoduodenal tumors. Acta Radiol 2006; 47: 248-256.
  107. Raufman J.P., Collins S.M., Pandol S.J. et al. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 1983; 84: 108-113.
  108. Rindi G., Kloppel G. Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 2004; 80: 12-15.
  109. Rindi G., Klöppel G., Alhman H. et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401.
  110. Rode J., Dhillon A.P., Doran J.F. et al. PGP 9.5, a new marker for human neuroendocrine tumors. Histopathology 1985; 9: 147-158.
  111. Roy P., Venzon D.J., Feigenbaum K.M. et al. Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis. A prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore) 2001; 80: 189-222.
  112. Roy P., Venzon D.J., Shojamanesh H. et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine 2000; 79: 379-411.
  113. Sarmiento J.M., Heywood G., Rubin J. et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197: 29-37.
  114. Sarmiento J.M., Que F.G., Grant C.S. et al. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 2002; 132: 976-982.
  115. Schindl M., Kaczirek K., Kaserer K. et al. Is the New Classification of Neuroendocrine Pancreatic Tumors of Clinical Help? World J Surg 2000; 24: 1312-1318.
  116. Semelka R.C., Custodio C.M., Cem B.N. Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging 2000; 11: 141-148.
  117. Service F.J., McMahon M.M., O'Brien P.C. et al. Functioning insulinoma - incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991; 66: 711-719.
  118. Service F.J., Natt N. The prolonged fast. J Clin Endocrinol Metab 2000; 85: 3973-3974.
  119. Sheppard B.C., Norton J.A., Doppman J.L. et al. Management of islet cell tumors in patients with Multiple Endocrine Neoplasia: A prospective study. Surgery 1989; 106: 1108-1117.
  120. Shoup M., Brennan M.F., McWhite K. et al. The value of splenic preservation with distal pancreatectomy. Arch Surg 2002; 137: 164-168.
  121. Skogseid B., Oberg K., Akerstrom G. et al. Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization? World J Surg 1998; 22: 673-677.
  122. Solcia E., Capella C., Kloppel G. et al. Endocrine tumours of the gastrointestinal tract. Histological typing of endocrine tumours. Berlin: Springer-Verlag 2000; 61-68.
  123. Solcia S.F., Rindi G., Bonato M. et al. Pancreatic Endocrine Tumors: General Concepts; Non-Functioning Tumors and Tumors with Uncommon Function. Boca Raton, CRC Press 1991.
  124. Solorzano C.C., Lee J.E., Pisters P.W. et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001; 130: 1078-1085.
  125. Stabile B.E., Morrow D.J., Passaro E. The gastrinoma triangle: operative implications. Am J Surg 1984; 147: 25-31.
  126. Stivanello M., Berruti A., Torta M. et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumors. A single institution experience. Ann Oncol 2001; 12 (suppl 2): 73-77.
  127. Sugg S.L., Norton J.A., Fraker D.L. et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg 1993; 218: 138-144.
  128. Sutliff V.E., Doppman J.L., Gibril F. et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997; 15: 2420-2431.
  129. Tagaya N., Ishikawa K., Kubota K. Spleen-preserving laparoscopic distal pancreatectomy with conservation of the splenic artery and vein for a large insulinoma. Surg Endosc 2002; 16: 217-218.
  130. Takamatsu S., Teramoto K., Inoue H. et al. Laparoscopic enucleation of an insulinoma of the pancreas tail. Surg Endosc 2002; 16: 217.
  131. Thom A.K., Norton J.A., Axiotis C.A. et al. Location, incidence and malignant potential of duodenal gastrinomas. Surgery 1991; 110: 1086-1093.
  132. Thomas-Marques L., Murat A., Delemer B. et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006; 101: 266-273.
  133. Thompson G.B., van Heerden J.A., Grant C.S. et al. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery 1988; 104: 1011-1017.
  134. Triponez F., Goudet P., Dosseh D. et al. Is surgery beneficial for MEN1 patients with small (≤2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006; 30: 654-662.
  135. Tucker O.N., Crotty P.L., Conlon K.C. The management of insulinoma. British Journal of Surgery 2006; 93: 264-275.
  136. Weber H.C., Venzon D.J., Jensen R.T. et al. Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori and proton pump inhibitor therapy. Gastroenterology 1997; 112: 84-91.
  137. Weber H.C., Venzon D.J., Lin J.T. et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108: 1637-1649.
  138. White T.J., Edney J.A., Thompson J.S. et al. Is there a prognostic difference between functional and nonfunctional islet cell tumors? Am J Surg 1994; 168: 627-629.
  139. Wiedenmann B., Franke W.W., Kuhn C. et al. Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA 1986; 83: 3500-3504.
  140. Wiedenmann B., Jensen R.T., Mignon M. et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 1998; 22: 309-318.
  141. Yao J.C., Hassan M., Phan A. et al. One Hundred Years After "Carcinoid": Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J Clin Oncol 26: 3063-3072.
  142. Yao J.C., Phan A.T., Chang D.Z. et al. Efficacy of RAD001 (Everolimus) and octreotide LAR in advanced low-to-intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-4318.
  143. Yu F., Venzon D.J., Serrano J. et al. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 1999; 17: 615-630.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.